Marine Drugs (May 2020)

Antimycobacterial Activity of Laurinterol and Aplysin from <i>Laurencia johnstonii</i>

  • Sara García-Davis,
  • Karla Leal-López,
  • Carmen A. Molina-Torres,
  • Lucio Vera-Cabrera,
  • Ana R. Díaz-Marrero,
  • José J. Fernández,
  • Pilar Carranza-Rosales,
  • Ezequiel Viveros-Valdez

DOI
https://doi.org/10.3390/md18060287
Journal volume & issue
Vol. 18, no. 6
p. 287

Abstract

Read online

Marine environments represent a great opportunity for the discovery of compounds with a wide spectrum of bioactive properties. Due to their large variety and functions derived from natural selection, marine natural products may allow the identification of novel drugs based not only on newly discovered bioactive metabolites but also on already known compounds not yet thoroughly investigated. Since drug resistance has caused an increase in infections by Mycobacterium tuberculosis and nontuberculous mycobacteria, the re-evaluation of known bioactive metabolites has been suggested as a good approach to addressing this problem. In this sense, this study presents an evaluation of the in vitro effect of laurinterol and aplysin, two brominated sesquiterpenes isolated from Laurencia johnstonii, against nine M. tuberculosis strains and six nontuberculous mycobacteria (NTM). Laurinterol exhibited good antimycobacterial activity, especially against nontuberculous mycobacteria, being remarkable its effect against Mycobacterium abscessus, with minimum inhibitory concentration (MIC) values lower than those of the reference drug imipenem. This study provides further evidence for the antimycobacterial activity of some sesquiterpenes from L. johnstonii, which can be considered interesting lead compounds for the discovery of novel molecules to treat NTM infections.

Keywords